Journals / Türk Onkoloji Dergisi / 2021 / Cilt: 36 - Sayı: 4

Compatibility of MRI and Pathological Tumor Regression Grading in Patients with Locally Advanced Rectal Cancer After Undergoing Neoadjuvant Chemoradiotherapy

Pages
468–477
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was compatibility between mrTRG and pTRG, as expected, but this compatibility was found to be low.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE The compatibility between magnetic resonance imaging tumor regression grade (mrTRG) and pathological tumor regression grade (pTRG) was examined in patients with locally advanced rectal cancer (LARC) who underwent neoadjuvant chemoradiotherapy (nCRT).
📊
Key Findings & Data:RESULTS Median patient age was 61 years (range, 26–79 years), and 18 (43.9%) were female.
💡
Conclusion & Impact:There was compatibility between mrTRG and pTRG, as expected, but this compatibility was found to be low.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE The compatibility between magnetic resonance imaging tumor regression grade (mrTRG) and pathological tumor regression grade (pTRG) was examined in patients with locally advanced rectal cancer (LARC) who underwent neoadjuvant chemoradiotherapy (nCRT). The primary endpoint of the study was to evaluate the relationship between mrTRG and pTRG after nCRT. The secondary endpoint of the study was to evaluate the variables that affect mrTRG and pTRG. METHODS Forty-one patients with LARC treated with nCRT were analyzed. Magnetic resonance imaging (MRI) performed after nCRT was compared with MRI taken before nCRT. Changes in T and N stages and extramural vascular invasion positivity were investigated. TRG was divided into five groups in terms of pathological and MRI. The Dworak pTRG system was used for compatibility testing. MRI sensitivity and specificity were evaluated by comparing MRI-based response assessment with pathological assessment after nCRT. RESULTS Median patient age was 61 years (range, 26–79 years), and 18 (43.9%) were female. The relationship between mrTRG and pTRG was evaluated with the Cohen kappa coefficient. Significant compatibility was observed between pTRG and mrTRG (p=0.002), but the compatibility was low (kappa compatibility, 0.319). The sensitivity of mrTRG was 90% (18/20); specificity was 14.3% (3/21); positive predictive value was 85.7% (18/21); and negative predictive value was 90% (18/20). While pTRG was negatively affected by advanced age (p=0.037), mrTRG was adversely affected by advanced post-nCRT N stage (p=0.048). CONCLUSION As age increased, pTRG was negatively affected; as the post-nCRT N stage increased, mrTRG was negatively affected. There was compatibility between mrTRG and pTRG, as expected, but this compatibility was found to be low.

🔖

Cite This Article

AKAY, E., ARAL, İ. P., ARSLAN, A., EREN, S. K., TÜRK, G., ÖZHAN, N. (2022). Compatibility of MRI and Pathological Tumor Regression Grading in Patients with Locally Advanced Rectal Cancer After Undergoing Neoadjuvant Chemoradiotherapy. Türk Onkoloji Dergisi, Cilt: 36 - Sayı: 4, 468–477. https://ajindex.com/articles/639099

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Horvat N, Petkovska I, Gollub MJ. MR ımaging of rectal cancer. Radiol Clin N Am 2018;56:75
  2. Gollub MJ, Arya S, Beets-Tan RG, DePrisco G, Gonen M, Jhaveri K, et al. Use of magnetic resonance imaging in rectal cancer patients: Society of Abdominal Radiology (SAR) rectal cancer disease-focused panel (DFP) recommendations 2017. Abdom Radiol 2018;43(11):2893–902
  3. Horvat N, Rocha CC, Oliveira BC, Petkovska I, Gollub MJ. MRI of rectal cancer: Tumor staging, ımaging techniques, and management. Radiographics. 2019;39:367–87
  4. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Pre-operative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351(17):1731–40
  5. Lambregts DM, Boellaard TN, Beets-Tan RG. Response evaluation after neoadjuvant treatment for rectal cancer using modern MR imaging: A pictorial review. Insights Imaging 2019;10(1):15
  6. Braun OM, Neumeister B, Popp W, Scherrer R, Dobrowsky E, Dobrowsky W, et al. Histologic tumor regression grades in squamous cell carcinoma of the head and neck after pre-operative radiochemotherapy. Cancer 1989;63(6):1097–100
  7. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry‐Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after pre-operative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73(11):2680–6
  8. Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 2002;20(14):3061–71
  9. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98(7):1521–30. 10.Dhadda AS, Dickinson P, Zaitoun AM, Gandhi N, Bessell EM. Prognostic importance of Mandard tumor regression grade following pre-operative chemo/ radiotherapy for locally advanced rectal cancer. Eur J Cancer 2011;47(8):1138–45. 11.Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after pre-operative chemoradiotherapy for locally advanced rectal carcinoma revisited: Updated results of the CAO/ ARO/AIO-94 trial. J Clin Oncol 2014;32(15):1554–62. 12.Rodel C, Martus P, Papadoupolos T. Prognostic significant for tumor regression after pre-operative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23(34):8688–96. 13.Dworak O, K